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1 | INTRODUC TION














tinuation	due	 to	adverse	events.2	This	was	especially	 true	 for	HCV/
HIV‐coinfected	LT	recipients,	in	whom	the	SVR	rate	was	14%	to	21%,	
which	was	significantly	lower	than	in	HCV‐monoinfected	recipients.7,8











of	 severe	HCV	 infection	 or	 cirrhosis	 received	 SOF‐based	 antiviral	
therapy.	SVR	was	89%	and	was	followed	by	improved	liver	function	




























































currence	of	HCV	 infection	 in	HIV‐infected	 individuals	were	highly	effective	and	
well	tolerated,	with	results	comparable	to	those	of	HCV‐monoinfected	patients.
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We	 performed	 a	 multicenter	 nationwide	 cohort	 study	 of	 250	
consecutive	HCV/HIV‐coinfected	patients	who	underwent	LT	be‐
tween	2002	and	2012	 in	Spain	and	who	were	prospectively	 fol‐




coinfection,	 and	presence	of	 hepatocellular	 carcinoma.	Only	 co‐
infected	patients	who	had	received	posttransplant	INF‐free	anti‐
HCV	 therapy	 and	 for	 whom	 there	 were	 matched	 monoinfected	
controls	 treated	 against	 HCV	 in	 the	 same	 center	were	 included	











as	 previously	 described.7	 Information	 for	 each	 patient	 was	 re‐
corded	 before	 treatment,	 and	 at	 1,	 3,	 6,	 9,	 and	 12	months	 after	
starting	anti‐HCV	therapy.	The	variables	collected	are	presented	
in	 Tables	 1‒5.	 Patient	 information	 was	 sent	 to	 the	 coordinating	
center	 every	 6	months	 and	 entered	 into	 the	 FIPSE	 LT‐HIV‐05‐
GESIDA	 45‐05	 database	 (available	 at	 https://www.seif88.com/






2.2 | Diagnosis of recurrent hepatitis C
Patients	 were	 diagnosed	 with	 recurrent	 hepatitis	 C	 when	 they	
had	both	positive	serum	HCV	RNA	after	LT,	and	histological	and/
or	 biochemical	 evidence	 of	 hepatitis	 (increased	 serum	 transami‐
nases	 for	 no	 other	 apparent	 reason	 and	 stable	 immunosuppres‐
sion).	Fibrosis	stage	was	established	on	the	basis	of	liver	histology	
(METAVIR	scale)	or	liver	stiffness	measurement.18	Fibrosing	chole‐
static	 hepatitis	 was	 defined	 according	 to	 standard	 histological	
criteria.19	 Severe	histologically	 proven	 recurrent	 hepatitis	C	was	
defined	 as	 the	 development	 of	 fibrosing	 cholestatic	 hepatitis	 or	
fibrosis	stage	F3/F4.
2.3 | Antiviral therapy with INF‐free regimens
Antiviral	 therapy	 was	 selected	 by	 the	 treating	 physician	 based	
on	 current	 guidelines	 and	 the	 regimens	 available	 at	 the	 time	 of	





ing	 to	 the	 recommendations	of	 the	package	 insert.	The	usage	and	
dose	 of	 RBV	were	 also	 decided	 by	 the	 treating	 physician	 accord‐
ing	 to	 the	European	 treatment	 regimen	 recommendations	and	 the	
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TA B L E  1  Characteristics	of	LT	recipients	receiving	DAAs	according	to	HIV	infection	status
ALL HIV+ HIV‐ P value
No.	of	cases 195 47 148
Demographic	data
Male	recipients 156	(80.0%) 36	(76.6%) 120	(81.1%) .645




6.37	[5.88;6.70] 6.29	[5.84;6.67] 6.38	[5.95;6.71] .277
Fibrosis	stage*
F0 8	(4.10%) 0	(0.00%) 8	(5.41%) .256
F1 38	(19.5%) 12	(25.5%) 26	(17.6%)
F2 33	(16.9%) 10	(21.3%) 23	(15.5%)
F3 37	(19.0%) 4	(8.51%) 33	(22.3%)
F3‐F4	vs	F0‐F2 79	(40.5%) 21	(44.7%) 58	(39.2%) .272
F4	vs	F0‐F3 116	(59.5%) 25	(53.2%) 91	(61.5%) .583
HCV	genotype
1 148	(75.9%) 27	(57.4%) 121	(81.8%) .175
1a 41	(21.0%) 10	(21.3%) 31	(20.9%)
1b 84	(43.1%) 8	(17.0%) 76	(51.4%)
1a/b 3	(1.54%) 1	(2.13%) 2	(1.35%)
Non‐subtypable 20	(10.3%) 8	(17.0%) 12	(8.11%)
3 23	(11.8%) 8	(17.0%) 15	(10.1%)
4 22	(11.3%) 11	(23.4%) 11	(7.43%)
Other/missing/non‐typable 2	(1.03%) 1	(2.13%) 1	(0.68%)
IFN‐free	treatment	regimen
SOF	+	DCV	±	RBV 54	(27.7%) 16	(34.0%) 38	(25.7%) .539
SOF	+	LDV	±	RBV 66	(33.8%) 17	(36.2%) 49	(33.1%)
SOF	+	SMV	±	RBV 59	(30.3%) 10	(21.3%) 49	(33.1%)
SMV	+	DCV	±	RBV 10	(5.13%) 3	(6.38%) 7	(4.73%)
3D	±	RBV 6	(3.08%) 1	(2.13%) 5	(3.38%)
SOF	+	DCV 24	(12.3%) 10	(21.3%) 14	(9.46%) .358
SOF	+	LDV 19	(9.74%) 7	(14.9%) 12	(8.11%)
SOF	+	SMV 13	(6.67%) 0	(0.00%) 13	(8.78%)
SMV	+	DCV 3	(1.54%) 0	(0.00%) 3	(2.03%)
SOF	+	DCV	+	RBV 30	(15.4%) 6	(12.8%) 24	(16.2%)
SOF	+	LDV	+	RBV 47	(24.1%) 10	(21.3%) 37	(25.0%)
SOF	+	SMV	+	RBV 46	(23.6%) 10	(21.3%) 36	(24.3%)
SMV	+	DCV	+	RBV 7	(3.59%) 3	(6.38%) 4	(2.70%)
3D	+	RBV 6	(3.08%) 1	(2.13%) 5	(3.38%)
DDAs	+	RBV 136	(69.7%) 30	(63.8%) 106	(71.6%) .393
RBV	doses	(mg)	at	treatment	start 800	[600;1000] 800	[600;800] 800	[600;1000] .397
Treatment‐experienced 87	(44.6%) 22	(46.8%) 65	(43.9%) .278
Months	between	LT	and	first	anti‐HCV	
treatment
43.8	[16.5;78.7] 41.3	[16.7;68.4] 45.0	[16.5;79.9] .144
Months	between	LT	and	DAA‐based	anti‐HCV	
treatment
76.1	[51.7;104] 71.2	[57.2;100] 78.1	[49.9;107] .618
Length	of	treatment	with	DAA‐based	
anti‐HCV	treatment	(weeks)
12.4	[12.0;23.9] 12.4	[12.0;23.9] 12.4	[12.0;23.9] .988
(Continues)























Categorical	 variables	were	expressed	as	a	 frequency	 (percentage).	
Continuous	variables	were	expressed	as	mean	(standard	deviation)	
or	median	(interquartile	range).	As	HIV+	individuals	were	originally	
matched	 in	 a	 proportion	 1:3	 with	 HCV‐monoinfected	 individuals,	
conditional	 logistic	 regression	was	 used	 to	 compare	 variables	 be‐









The	 study	 population	 comprised	 195	 LT	 recipients	 who	 received	




49	years.	 The	median	 time	 from	 LT	 to	 initiation	 of	 treatment	was	
76.1	months	 (IQR:	51.7‐104).	At	the	time	of	antiviral	therapy,	most	
patients	 had	 significant	 fibrosis	 or	 cirrhosis	 (F2‐F4,	 n	=	95,	 63.3%)	
and	were	receiving	tacrolimus‐based	 immunosuppression	 (n	=	134,	
70.8%).	 Most	 of	 the	 patients	 were	 treated	 with	 the	 combination	













nonboosted	 INSTI	 (raltegravir,	 two	cases;	dolutegravir,	 two	cases).	
The	other	case	was	a	patient	with	a	multidrug‐resistant	virus	who	




3.2 | Efficacy of antiviral therapy
The	antiviral	regimen	administered	is	shown	in	Table	1.	Combinations	
including	SMV	(SMV	+	SOF	and	SMV	+	DCV	with	or	without	RBV)	
were	 the	most	commonly	administered	 to	HIV	negative	 recipients	
(82%	of	patients	receiving	SMV	were	HIV	negative),	but	the	differ‐






individuals	 receiving	 suboptimal	 combinations	 such	 as	 SMV	+	SOF	
or	SMV	+	DCV	were	those	on	RBV	(P	=	.004).	The	SVR	rate	was	94%	
in	 HCV/HIV‐coinfected	 patients	 and	 95%	 in	 HCV‐monoinfected	
ALL HIV+ HIV‐ P value
Immunosuppression	at	treatment	start
Cyclosporine‐based 24	(12.3%) 9	(19.1%) 15	(10.1%) .215
Tacrolimus‐based 138	(70.8%) 29	(61.7%) 109	(73.6%)
Other	regimens 33	(16.9%) 9	(19.1%) 24	(16.2%)
LT,	 liver	 transplantation;	 SOF,	 sofosbuvir;	 SMV,	 simeprevir;	 DCV,	 daclatasvir;	 LDV,	 ledipasvir;	 RBV,	 ribavirin;	 DAA,	 direct‐acting	 antiviral,	 3D,	
Paritaprevir/Ritonavir/Ombitasvir.
TA B L E  1   (Continued)
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patients	(P	=	.239)	(Table	2).	Interestingly,	the	mITT	RVR	(week	4	of	
antiviral	 therapy)	 was	 significantly	 better	 in	 HCV/HIV‐coinfected	
patients	 than	 in	 HCV‐monoinfected	 recipients	 (100%	 vs.	 75.8%;	
P	=	.004).	Treatment	failures	(n	=	10)	were	due	to	relapse	in	six	cases,	
viral	breakthrough	 in	 three,	 and	death	during	 therapy	 in	one	case	













that	 in	genotype	4–infected	patients,	SVR	 tended	 to	be	 lower	 (al‐
beit	 not	 significantly)	 in	 HCV/HIV‐coinfected	 patients	 than	 in	





the	 HIV‐infected	 patients	 needed	 to	 stop	 them	 because	 of	 ad‐
verse	events.	Only	one	HCV‐monoinfected	cirrhotic	patient	died	
during	 therapy	 (liver	 decompensation).	 Three	 out	 of	 47	 (6.38%)	








served	 that	 HIV‐positive	 recipients	 more	 frequently	 underwent	 a	
decrease	 in	 calcineurin	 inhibitor	 (CNI)	 dose	 (P	=	.006)	 and	 the	 ad‐
dition	of	another	 IS	drug	 (P	=	.013),	mainly	mycophenolate	 (MMF).	
These	data	are	shown	 in	Table	S6.	Despite	 the	need	for	 IS	adjust‐
ment,	none	of	the	patients	developed	T‐cell	mediated	rejection.
3.3 | Impact of therapy on liver tests
As	expected,	there	was	a	significant	 improvement	 in	transaminase	





MELD	at	 the	 time	of	 SVR	 (as	 compared	 to	baseline)	 in	 coinfected	
patients	with	SVR.
3.4 | Impact of therapy on hematological, renal, and 
HIV virological test results
As	expected	with	the	concomitant	use	of	RBV	in	some	patients,	
a	 significant	decrease	 in	hemoglobin	 levels	was	observed	 in	 the	
TA B L E  2  Virological	response	to	IFN‐free	treatment	in	HIV/
HCV‐coinfected	and	HCV‐monoinfected	liver	transplant	recipients	
[95%CI]
HIV+ HIV‐ P value
Overall,	n 47 148
Week	4 100	[92.3;100] 75.8	[67.3;83]a .004
EOT 95.7	[85.5;99.5] 98	[94.2;99.6] .239
SVR 93.6	[82.5;98.7] 95.3	[90.5;98.1] .239
Genotype	1,	n 27 120
Week	4 100	[87.2;100] 76.5	[67;84.3] .138
EOT 100	[87.2;100] 97.5	[92.9;99.5] 1.000




Week	4 100	[69.2;100] 100	[88.8;100] .
EOT 100	[69.2;100] 100	[88.8;100] .




Week	4 100	[63.1;100] 72.7	[60.4;83] .239
EOT 100	[63.1;100] 97.4	[90.8;99.7] 1.000




Week	4 100	[2.5;100] 50	[1.3;98.7] 1.000
EOT 100	[2.5;100] 100	[15.8;100] .
SVR 100	[2.5;100] 100	[15.8;100] .
Genotype	3 8 15
Week	4 100	[63.1;100] 63.6	[30.8;89.1] .239
EOT 100	[63.1;100] 100	[78.2;100] .
SVR 100	[63.1;100] 100	[78.2;100] .
Genotype	4,	n 11 11
Week	4 100	[69.2;100] 77.8	[40;97.2] 1
EOT 81.8	[48.2;97.7] 100	[71.5;100] .476









Week	 4,	 early	 virological	 response,	 EOT,	 end	 of	 treatment	 response;	
SVR,	sustained	virological	response.
aWeek	4	results	not	available	in	25	HIV‐negative	patients.	
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coinfected	 cohort,	 with	 mean	 values	 of	 143	g/L	 at	 the	 initia‐
tion	of	treatment	and	129	g/L	at	the	end	(P	=	.001).	However,	as	
stated	 above,	 only	 three	 patients	 (6.38%)	 required	 hematopoi‐
etic	growth	factors	and	none	stopped	antiviral	treatment.	There	
was	 a	 significant	 increase	 in	 the	 platelet	 count	 (127	×	109/L vs. 
150	×	109/L,	respectively;	P	=	.001).	No	significant	changes	were	
observed	in	other	hematological	parameters,	such	as	white	blood	
cells,	 neutrophils,	 lymphocytes,	 and	 CD4+	 T	 cells	 (Table	 5)	 nor	
in	renal	 function	test	 (creatinine,	estimated	glomerular	filtration	





in	 HIV‐negative	 HCV‐infected	 LT	 recipients,9‒12,20	 data	 on	 HCV/
HIV‐coinfected	 LT	 recipients	 remain	 scarce	 and	 are	based	only	on	
small case series.13‒17	We	report	the	results	of	the	first	nationwide,	
multicenter,	prospective	case‐control	study	on	the	effectiveness	and	
tolerability	 of	 antiviral	 therapy	with	DAAs	 in	HCV/HIV‐coinfected	
patients	with	recurrence	of	hepatitis	C	after	LT	and	a	matched	cohort	




In	 the	 IFN	era,	 the	SVR	rate	 in	coinfected	LT	 recipients	with	 re‐
currence	of	hepatitis	C	was	significantly	lower	than	in	HCV‐monoin‐
fected	 patients.	 A	 prospective	 cohort	 study	 by	 our	 group	 (FIPSE	
Investigators)7	 showed	 that	 the	 SVR	 rate	 was	 significantly	 lower	 in	
coinfected	than	in	monoinfected	LT	recipients	(21%	vs.	36%;	P	=	.013).	
Treatment	 discontinuation	 was	 also	 significantly	 more	 frequent	 in	
coinfected	recipients	(56%	vs.	39%;	P	=	.016).	The	addition	of	a	first‐




(1)	 the	significant	number	of	adverse	events	observed	 in	 this	group;	
TA B L E  3  Characteristics	of	patients	whose	first	IFN‐free	treatment	regimen	failed
Patient HIV Sex HCV genotype Fibrosis stage
Previous decomp. 
HVC First IFN‐free regimen
Reason for 
failure
1 + M 1b F2 No SOF	+	SMV	+	RBV Relapse
2 + M 4 F4 Yes SMV	+	DCV	+	RBV Viral	
breakthrough
3 + M 4 F4 Yes SMV	+	DCV	+	RBV Viral	
breakthrough
4 ‐ M 1b F4 Yes SMV	+	DCV	+	RBV Relapse
5 ‐ M 1b F4 No SMV	+	DCV	+	RBV Viral	
breakthrough
6 ‐ M 1na F4 No SOF	+	DCV Death	during	
treatment
7 ‐ M 4 F3 No SOF	+	SMV Relapse
8 ‐ M 1b F4 Yes SOF	+	DCV Relapse
9 ‐ F 1b F4 No SMV	+	DCV	+	RBV Relapse
10 ‐ F 1b F4 No SOF	+	LDV	+	RBV Relapse
M,	male;	F,	female;	Decomp,	decompensation;	na,	subtype	not	available,	SVR,	sustained	virological	response;	SOF,	sofosbuvir;	SMV,	simeprevir;	DCV,	
daclatasvir;	LDV,	ledipasvir;	RBV,	ribavirin.





At end, median 
[IQR] P value
ALT	(U/L) 52.0	[33.0;96.2] 18.5	[16.0;24.5] <.001




AP	(U/L) 112	[93.5;145] 93.0	[79.0;135] .005












MELD 8.92	[7.34;11.8] 9.73	[8.06;11.2] .446
ALT,	alanine	aminotransferase;	AST,	aspartate	aminotransferase;	AP,	al‐
kaline	phosphatase;	eGFR,	estimated	glomerular	filtration	rate	(by	CKD‐
Epi);	 INR,	 international	 normalized	 ratio;	 MELD,	 Model	 for	 end‐stage	
liver disease.








The	 development	 of	 IFN‐free	 antiviral	 regimens	with	 different	
combinations	of	DAAs	has	completely	changed	the	treatment	of	pa‐
tients	who	experience	recurrence	of	hepatitis	C	after	transplantation.	

















in	 patients	 treated	 either	 with	 SOF	+	RBV	+	pegylated	 interferon,	
SOF	+	SMV	+	RBV	or	SOF	+	DCV).	Additional	24	cases	in	Italy16 and 




























load,	which	was	maintained	below	detection	 levels	 in	most	 cases.	
Immunosuppression	 adjustments	 were	 more	 frequently	 observed	






As	 expected	 after	 viral	 eradication,	 we	 observed	 an	 improve‐
ment	 in	 liver	 enzyme	 values.	However,	 this	 improvement	was	 not	
noted	in	tests	to	assess	liver	function,	such	as	bilirubin,	albumin,	INR,	
and	MELD	score.	This	discrepancy	could	have	been	due	to	the	short	
period	 over	 which	 these	 parameters	 changed,	 namely,	 from	 the	
TA B L E  5  Changes	in	lymphocyte,	CD4	and	CD4/CD8	T‐cell	
counts,	and	plasma	HIV	RNA	viral	load	from	initiation	to	end	of	
treatment	in	the	44	coinfected	patients	with	SVR
At initiation At end P value
Lymphocytesa 1505	(693) 1405	(903) .204
CD4	T‐cell	countb 366	[256;467] 398	[264;564] .145
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the	 largest	 series	 to	date	of	HCV/HIV‐coinfected	patients	 treated	
with	INF‐free	therapies	after	LT.	In	addition,	the	results	were	similar	
to	those	found	in	matched	HCV‐monoinfected	LT	recipients	treated	
with	 the	same	 INF‐free	 regimens	at	 the	same	sites.	Second,	a	 sig‐
nificant	proportion	of	patients	 received	 a	 suboptimal	 combination	
(SMV	+	SOF	or	SMV	+	DCV)	because	it	was	the	only	choice	available	
at	the	time	of	treatment.	This	had	a	negative	impact	on	SVR	results,	
especially	 in	 genotype	 4–infected	 liver	 recipients.	 Finally,	 several	
data	 are	 lacking	 in	 the	HCV‐monoinfected	 cohort,	mainly	 adverse	
events	 during	 antiviral	 therapy	 and	 changes	 in	 the	 results	 of	 liver	
function	tests	after	viral	eradication,	thus	precluding	a	robust	com‐
parison	of	monoinfected	patients	with	their	coinfected	counterparts.
In	 conclusion,	 treatment	 of	 post‐LT	 recurrence	 of	 hepatitis	 C	
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